New Life Pharma LLC
Has New Life Pharma LLC received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued New Life Pharma LLC a warning letter naming semaglutide and tirzepatide, dated Apr 14, 2026, with the FDA subject line “CGMP/Adulterated and Unapproved New Drug/Misbranded.” openFDA also lists 4 drug recall reports for the firm naming semaglutide and tirzepatide.
FDA records in this index name New Life Pharma LLC from Feb 26, 2026 to Apr 14, 2026.
- Type named in FDA records
- Not stated
- FDA warning letters
- 1
- Drug recall reports
- 4
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Apr 14, 2026
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Apr 14, 2026 | CGMP/Adulterated and Unapproved New Drug/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Apr 14, 2026: … the Federal Food, Drug, and Cosmetic Act (FD&C Act). Your “ Semaglutide Sterile Multi-Dose Vial” and “Tirzepatide Sterile … 331(p), and 355(a). Unapproved New Drug Violations Your “ Semaglutide Sterile Multi-Dose Vial” and “Tirzepatide Sterile … your registration as a drug manufacturer and listing of a semaglutide injectable drug in FDA’s drug registration and … Full letter
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Feb 26, 2026 | Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06 | Lack of Assurance of Sterility | Class II | Ongoing | D-0393-2026 |
| Feb 26, 2026 | Semaglutide Inj, 2mg x 10, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-07. | Lack of Assurance of Sterility | Class II | Ongoing | D-0392-2026 |
| Feb 26, 2026 | Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-04. | Lack of Assurance of Sterility | Class II | Ongoing | D-0395-2026 |
| Feb 26, 2026 | Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-03. | Lack of Assurance of Sterility | Class II | Ongoing | D-0394-2026 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Apr 14, 2026
- openFDA drug recall enforcement reports
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.